In order to manufacture innovative and proprietary products from abroad in China, transfer of technology and know-how under a licensing arrangement to a Chinese partner will be required.





Despite China’s reputation for weak protection of IP, the Chinese Government is determined to change this, particularly in the biopharmaceutical industry and great progress has been made 

There are over 1 million domestic patent applications in progress in China submitted by Chinese companies, which have fully understood the importance of Intellectual Property Protection. 

Stravencon is well acquainted with the IP regulatory regimen and is able to advise EU/US companies on strategies and approaches in this area.